Reflections on a month in the life of the Ontario Drug Benefit Plan

McIsaac, Warren; Naylor, C. David; Anderson, Geoffrey M.; O'Brien, Bernie J.
February 1994
CMAJ: Canadian Medical Association Journal;2/15/1994, Vol. 150 Issue 4, p473
Academic Journal
No abstract available.


Related Articles

  • Ontario Okays Prezista.  // Guide;Jul2007, Vol. 27 Issue 7, p89 

    The article reports on the approval of Prezista, a protease inhibitor made by Tibotec, by Health Canada. The Drug has been added to the Ontario Drug Benefit Formulary. The cost of Prezista will also be covered under the Ontario Drug Benefit Program. The Common Drug Review has recommended the...

  • Potentially Inappropriate Prescribing in Canada Relative to the US. Rochon, Paula A.; Lane, Christopher J.; Bronskill, Susan E.; Sykora, Kathy; Anderson, Geoffrey M.; Mamdani, Muhammad M.; Gurwitz, Jerry H.; Dhalla, Irfan A. // Drugs & Aging;2004, Vol. 21 Issue 14, p939 

    Objective: To explore the prescribing of potentially inappropriate drug therapy in Ontario, Canada where there is a restrictive drug formulary relative to the US where there is no single drug formulary. Methods: A retrospective, cohort study using an administrative database (Ontario, Canada)...

  • Ontario should replace age-based drug subsidies. ROVERE, MARK; BARUA, BACCHUS // Fraser Forum;Jul/Aug2011, p16 

    The article focuses on the savings that Ontario can gain by moving away from aged-based eligibility. Ontario operates the largest tax-payer funded drug plan through programs including the Ontario Drug Benefit (ODB), the Trillium Drug Program, the Special Drugs Program that cost over 4 billion...

  • Ontario recognizes bigger role for retail pharmacy.  // Chain Drug Review;5/23/2011, Vol. 33 Issue 9, p2 

    The article focuses on the statement of Dennis Darby, chief executive officer (CEO) of the Ontario Pharmacists' Association, regarding the benefits of the public drug program MedsCheck on seniors and Ontario Drug Benefit recipients in Ontario.

  • Ontario hunkers down in budget. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;5/15/2012, Vol. 184 Issue 8, pE418 

    The article offers information on the Strong Action for Ontario, a budget plan for health spending in Ontario for the fiscal year 2012. Ontario Finance Minister Dwight Duncan states that the major goal of the budget plan is to tighten up overall growth in Ontario's health spending to a 2.1%...

  • Ontario's law curbing the cost of generic drugs sparks changes for pharmacies and other Canadian buyers. Silversides, Ann // CMAJ: Canadian Medical Association Journal;8/4/2009, Vol. 181 Issue 3/4, pE43 

    The article focuses on Ontario's medical law which has curbed the cost of generic drugs and has sparked changes for pharmacies and other Canadian buyers. Reportedly, Canadian prices for generic drugs, copies of brand-name drugs have lost patent protection due to some complicated causes. It notes...

  • High prices of cancer drugs in the US not just about R&D.  // PharmacoEconomics & Outcomes News;10/19/2013, Issue 689, p4 

    The article presents research conducted in the U.S. which reflects on the reality of the true benefit and societal and personal costs of anticancer drugs to suggest scenarios for reduced drug pricing by linking price to the preservation and meaningful prolongation of life.

  • Reforming the Ontario Drug Benefit Plan:A missed opportunity. Rovere, Mark; Barua, Bacchus // Fraser Forum;Jul/Aug2012, p20 

    The article focuses on the Ontario Drug Benefit (ODB) plan and the plans to reform it. The authors mention that the provincial government of Ontario has missed a very important opportunity to improve its prescription drug program, as well as save taxpayers a significant amount of money. They...

  • Don't Be Steamrolled into Buying Medicare Part D. Hanson, Marshall // Officer;Sep2005, Vol. 82 Issue 7, p69 

    Focuses on the advantages and limitations of the Medicare Part D, the new Medicare Prescription Drug Program for senior military retirees. Choices for prescription drug coverage plans; Average monthly premium; Conflict with the TRICARE for Life plan.

  • Denosumab available for PMO in Ontario.  // PharmacoEconomics & Outcomes News;3/17/2012, Issue 649, p11 

    The article reports on the listing of denosumab by the Ontario government on the Ontario Drug Benefit (ODB) programme for the treatment of postmenopausal osteoporosis (PMO) in women at high risk for fracture.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics